EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer

Eva L Claassens, Linetta B Koppert, Carmen C van der Pol, Ernest J T Luiten, Thiemo J A van Nijnatten, Agnes Jager, Maaike de Boer, Paul J van Diest, Marjolein L Smidt, Janine M Simons, RISAS study group

European Journal of Surgical Oncology · 2026-06 · 52 (6) · 111785

DOI: 10.1016/j.ejso.2026.111785 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026-06. Verfasst von Eva L Claassens und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, M…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Lymph Nodes, Breast Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erasmus Medisch Centrum, Erasmus MC Kanker Instituut, Universiteit Maastricht.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsLymph NodesBreast NeoplasmsHumansFemaleNeoplasm StagingNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesRetrospective StudiesSentinel Lymph Node BiopsyChemotherapy, AdjuvantTrastuzumabAxillaMiddle AgedNeoplasm, ResidualLymphatic MetastasisLymph Node ExcisionAdo-Trastuzumab EmtansineCapecitabineAdultAged

Stichwörter der Autor:innen

Adjuvant systemic therapyAxillary staging proceduresHER2-Positive breast cancerPathologic complete responseTriple-negative breast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humanAdo-Trastuzumab EmtansineCapecitabine

Autor:innen und Institutionen

  • Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands. Electronic address:…
  • Department of Surgical Oncology, Erasmus Medical Centre Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Department of Surgical Oncology, Cancer Centre, University Medical Centre Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Alrijne Hospital, Leiderdorp, the Netherlands.
  • Department of Surgical Oncology, Amphia Hospital, Breda, the Netherlands; Department of Surgery College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, Abu Dhabi Emirate, United Arab Emirates.
  • GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlan…
  • Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands.

Förderung

  • Erasmus Medisch Centrum
  • Erasmus MC Kanker Instituut
  • Universiteit Maastricht
  • Roche Netherlands BV
  • KWF Kankerbestrijding

Zitieren

APA

Claassens, E. L., Koppert, L. B., van der Pol, C. C., Luiten, E. J. T., van Nijnatten, T. J. A., Jager, A., de Boer, M., van Diest, P. J., Smidt, M. L., Simons, J. M., & RISAS study group (2026). Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer. European Journal of Surgical Oncology, 52(6), 111785. https://doi.org/10.1016/j.ejso.2026.111785

Vancouver

Claassens EL, Koppert LB, van der Pol CC, Luiten EJT, van Nijnatten TJA, Jager A, et al. Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer. European Journal of Surgical Oncology. 2026;52(6):111785. doi:10.1016/j.ejso.2026.111785

BibTeX
@article{Claassens2026,
  author = {Claassens, Eva L and Koppert, Linetta B and van der Pol, Carmen C and Luiten, Ernest J T and van Nijnatten, Thiemo J A and Jager, Agnes and de Boer, Maaike and van Diest, Paul J and Smidt, Marjolein L and Simons, Janine M and RISAS study group, RISAS study group},
  title = {Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  volume = {52},
  number = {6},
  pages = {111785},
  doi = {10.1016/j.ejso.2026.111785}
}
Kostenlos starten →